Bladder Cancer Medications

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

Jelmyto is an alkylating drug approved for the treatment of low-grade urothelial cancer in the upper urinary tract.

Bavencio is a checkpoint inhibitor approved for advanced or metastatic bladder (urothelial) cancer—both as maintenance therapy and for patients who progress on chemotherapy—metastatic Merkel cell carcinoma and advanced kidney cancer (renal cell carcinoma).

Imfinzi is a checkpoint inhiibtor approved for advanced or metastatic bladder (urothelial) cancer, inoperable non-small-cell lung cancer and extensive-stage small cell lung cancer.

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. 

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, advanced stomach and esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. 

Tecentriq is a checkpoint inhibitor approved for the treatment of advanced or metastatic bladder (urothelial) cancer, metastatic non-small-cell lung cancer, extensive-stage small-cell lung cancer, metastatic liver cancer and inoperable or metastatic melanoma.

TICE is BCG bacteria approved to treat early-stage bladder (urothelial) cancer and prevent recurrence.

Balversa is a kinase inhibitor approved for previously treated locally advanced or metastatic bladder cancer (urothelial carcinoma) that carries FGFR genetic mutations.

Padcev is an antibody-drug conjugate approved for adults with locally advanced or metastatic bladder cancer and other urothelial cancers who previously received PD-1 or PD-L1 checkpoint inhibitors and platinum-based chemotherapy.

Rozlytrek is approved for the treatment of solid tumors anywhere in the body that have NTRK gene fusions and for ROS1-positive non-small-cell lung cancer.

Trodelvy is an antibody-drug conjugate approved for the treatment of metastatic triple-negative breast cancer and advanced bladder (urothelial) cancer.

Vitrakvi is a TRK inhibitor that works against cancers anywhere in the body with NTRK gene fusions.